A Longitudinal, Observational Biomarker Study in Pancreatic Cancer Patients Receiving Chemotherapy
- Conditions
- Pancreatic Cancer
- Registration Number
- NCT04281511
- Lead Sponsor
- National Cancer Center, Korea
- Brief Summary
1. Based on the literature, the pancreatic cancer treatment predictor biomarker, which is used in the domestic clinical field, is actually applied to the pancreatic cancer patient cohort of the National Cancer Center.
2. To systematically prospectively identify prospective treatment response biomarkers for Pancreatic Cancer Cohort in the National Cancer Center
- Detailed Description
1. Immunohistochemistry and gene test for hENT1, DCK, SMAD4, CES2, BRCA 1/2,PALB2, MMRd, MSI, Tumor Ag and etc. on Cancer sample
2. Collect data of Biomarker for pancreatic cancer
3. Compare with Big data and Cohort study in National cancer center
4. The number of subjects is changed by statistical consideration. 218-\>238
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 238
- Pathologically Confirmed Pancreatic Cancer Patients
- Subjects who do not agree with the study
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method median survival 5 years The length of time from either the date of diagnosis or the start of treatment for a disease,the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse
progressive-free survival 5 years The length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
NATIONAL CANCER CENTER 323, Ilsan-ro, Ilsandong-gu,
🇰🇷Goyang-si, Gyeonggi-do, Korea, Republic of